Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Drug Safety Oversight Board Adds Staff To Manage Operations

Executive Summary

FDA is adding three new staffers dedicated to working full time on the operations and communications of the Drug Safety Oversight Board

You may also be interested in...



DSOB adds staffer

Mary Mease joins FDA's Drug Safety Oversight Board as a science policy analyst, the agency announced Nov. 4. Mease previously worked in the Center for Drug Evaluation & Research's Division of Scientific Investigators; she has also worked as a safety evaluator in the Office of Drug Safety's Division of Drug Risk Evaluation. Mease's appointment is expected to complete the board's staff (1"The Pink Sheet" Oct. 24, 2005, p. 5)...

DSOB adds staffer

Mary Mease joins FDA's Drug Safety Oversight Board as a science policy analyst, the agency announced Nov. 4. Mease previously worked in the Center for Drug Evaluation & Research's Division of Scientific Investigators; she has also worked as a safety evaluator in the Office of Drug Safety's Division of Drug Risk Evaluation. Mease's appointment is expected to complete the board's staff (1"The Pink Sheet" Oct. 24, 2005, p. 5)...

FDA Public Meeting On Rx Risk, Benefit Communication Slated For December

FDA will hold a public hearing on ways to better communicate information about drug risks and benefits, FDA Drug Safety Oversight Board Executive Director Susan Cummins said at the PDA/FDA Joint Regulatory Conference in Washington, D.C. on Sept. 13

Related Content

Topics

UsernamePublicRestriction

Register

PS046468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel